Alzheimer's
42 articles on Alzheimer's, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic Culture: Why Medical Weight Loss Needs Better Guardrails
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
7 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond Appetite: How GLP-1 Drugs May Be Rewiring the Human Brain
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
7 min read
Beyond Weight Loss: Surprising Health Benefits of GLP-1 Drugs
While widely recognized for their effectiveness in weight management, GLP-1 receptor agonists are revealing a spectrum of profound health benefits. Discover how these groundbreaking medications are impacting cardiovascular health, kidney function, liver disease, and even potentially neurodegenerative conditions.
7 min read
Mediterranean Diet's Cellular Secret: Unlocking Anti-Aging Proteins
A groundbreaking study reveals that the Mediterranean diet may boost cellular health by activating specific mitochondrial microproteins, offering a new perspective on its profound anti-aging benefits.
7 min read
Understanding Insulin Resistance: Beyond Blood Sugar
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
8 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
GLP-1 Drugs: New Hope for Depression and Motivation?
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
8 min read
GLP-1 Drugs: Beyond Weight Loss – New Benefits and Risks Emerge
GLP-1 medications are revolutionizing weight management and diabetes care, but their impact extends far beyond the scale. This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers.
8 min read
Kathryn Thomas: Daughter Ellie 'Getting Her Head Around' Famous Mum
Irish broadcaster Kathryn Thomas reveals her eldest daughter Ellie is starting to grasp that her mum is a public figure, amid chats about fame and family. In her new documentary Young Forever: The Death of Ageing?, she explores aesthetics, Botox normalization, peptides, and biohacking for longevity. As a 47-year-old mum, she emphasizes aging as a privilege while focusing on health for her kids' milestones.
6 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
GLP-1 Microdosers Chase Longevity: Survey Insights
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
5 min read
Sex-Specific GLP-1 Brain Atlas Reveals Drug Impact Differences
A new peer-reviewed study from Mount Sinai researchers has created the first sex-specific atlas of GLP-1 expression in the mouse brain, revealing dramatic differences between males and females. These insights into drugs like semaglutide and liraglutide could reshape treatments for obesity, diabetes, and even psychiatric disorders. Key hindbrain and olfactory bulb variations highlight why GLP-1 effects on appetite and weight loss differ by sex.
5 min read
This Week in Science: Ozempic's Joint Benefits, Superagers Secrets & More
This week's science news uncovers surprising benefits of Ozempic for joint health beyond weight loss, reveals why superagers stay sharp with more new brain neurons, and highlights food quality over diet type for heart protection. From cholesterol-lowering oatmeal diets to a universal nasal vaccine, these findings offer fresh hope for metabolic and cognitive health.
5 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
Ireland Set to Ride Weight-Loss Drug Revolution with Eli Lilly
Just as smartphones propelled Ireland's economy post-financial crisis, GLP-1 weight-loss drugs like Eli Lilly's Mounjaro and Zepbound are set to do the same. With factories in Kinsale and Limerick producing key ingredients, Ireland eyes massive tax windfalls and export spikes. Gallup data shows US obesity falling to 37%, crediting these therapies.
5 min read
Supplements Obsession Booms: Inside Thorne Factory as Doctors Stay Wary
Stepping into Thorne's vast supplement factory, the scent of mixed berries hits like childhood nostalgia amid pallets of creatine and berberine. As the industry explodes to $100-200B globally, with 75% of US adults now supplementing, doctors warn of risks in this unregulated minefield. Inside, rigorous testing sets Thorne apart—but is it enough?
6 min read
Billion-Dollar Longevity Business: Adding Years to Life
The aging population's Silver Tsunami is reshaping global economies, but the Longevity Investors Lunch offers a beacon of innovation. From ultra-personalized medicine to bio-avatars and surging GLP-1 valuations, investors are betting billions on extending healthy lifespans. Yet, warnings about risky supplements highlight the path ahead.
6 min read
BPC-157: Hype, Science, and Safety Risks Explained
BPC-157 promises rapid healing for injuries and inflammation, but nearly all evidence comes from animal studies with scant human trials. As hype surges in wellness circles and amid policy shifts, experts urge caution due to safety unknowns and FDA prohibitions. This guide breaks down the science, risks, and what patients need to know.
5 min read
Brain Insulin Resistance: Driving Alzheimer's as Type 3 Diabetes
Alzheimer's disease may be more than just amyloid plaques—emerging evidence points to brain insulin resistance as a core driver, earning it the label 'Type 3 diabetes.' A recent Polish study uncovers how impaired insulin signaling starves neurons of energy and accelerates toxic protein buildup. Discover the science and potential therapies like GLP-1 agonists that could change the game.
5 min read
GLP-1 Market Boom to $299B by 2033: Drugs & Insights
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
4 min read
Individuals Stopping GLP-1 Medications Encounter Abrupt and Intense Hunger
GLP-1 receptor agonists, such as Wegovy and Ozempic, offer significant weight loss and health benefits but stopping them can lead to quick weight regain and rebound hunger. A University of Oxford study reveals that users often return to pre-treatment weights within 1.7 years, with health markers bouncing back even faster. Experts stress the need for comprehensive long-term strategies to manage obesity effectively.
3 min read
Novo Nordisk's Extended Strategy with Weight Loss Medications Fuels Scientific Enthusiasm, Though Wall Street Remains Uneasy
Novo Nordisk has faced challenges with its stock and leadership due to the weight loss drug market. While scientists see potential in GLP-1 medications expanding beyond diabetes and obesity, investors are losing patience. Ongoing research highlights additional benefits like reducing cravings and aiding brain functions.
3 min read
Semaglutide Fails to Slow Alzheimer's Progression in Study
A recent clinical trial, Evoke, investigated semaglutide's potential to slow Alzheimer's disease. While the drug improved certain Alzheimer's-related biomarkers, it did not delay the disease's progression. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
Healthcare Costs in 2026: Some Will Pay More, Others Less
The healthcare landscape will undergo significant changes in 2026. Negotiated Medicare drug prices offer relief to some, but the expiration of Affordable Care Act tax credits and Medicaid uncertainties will increase costs for others.
6 min read
Trinny Woodall's Saturday Routine: My Rest Day Involves Eating What I Want
Trinny Woodall shares her Saturday routine, emphasizing rest and indulgence. From morning supplements and walks to evening skincare and family time, discover how she balances self-care and relaxation.
4 min read
GLP-1 Agonist Market Surge: A Metabolic Shift Transforming Diabetes Treatment and Global Obesity Management
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
4 min read
Can Ozempic Be Used for Addiction Treatment?
The idea that Ozempic could treat addictions is gaining traction online, but it's crucial to examine the scientific basis for these claims. While some studies explore its impact on reward mechanisms, the drug's effects on the brain are not fully understood.
3 min read
Cleveland Clinic Reverses Type 2 Diabetes Using AI, Not GLP-1 Drugs
The Cleveland Clinic is utilizing an AI-powered approach to reverse type 2 diabetes. This innovative method focuses on creating a 'digital twin' of a patient's metabolism, leading to significant improvements in health markers and a reduction in medication dependence.
10 min read
Are Microdoses of GLP-1s the New Fitness Trend? Weighing Benefits and Risks
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
8 min read
Generic Drug Manufacturers Eye Price Adjustments as Novo Reduces Wegovy Costs
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
3 min read
Belly Fat Linked to Brain Aging, While Muscle Mass Keeps Brains Young
New research indicates a connection between body composition and brain aging. The study suggests that individuals with more muscle mass and less hidden belly fat tend to have younger-appearing brains, as observed through MRI scans.
4 min read
Semaglutide Fails to Slow Advancement of Alzheimer's Disease
Results from a recent trial indicate that semaglutide, typically used for obesity, did not slow the progression of Alzheimer's disease. While the drug improved Alzheimer's-related biomarkers, this did not translate to a delay in the disease's advancement. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
Another Round of Weight-Loss Medications is on the Horizon
The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.
4 min read
The Heated Race to Dominate the Booming GLP-1 Medication Arena
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
3 min read
A Peek Inside Dominic Cummings' Ambitious Lab Aiming for an 'Ozempic Moment'
Dominic Cummings' vision for a groundbreaking research agency is gaining momentum with cross-party support and substantial funding. ARIA aims to revolutionize the UK through cutting-edge technologies and entrepreneurial science, seeking its own 'Ozempic moment'.
5 min read
GLP-1 Weight Loss Drugs: Global Expansion & What It Means for Your Health
GLP-1 drugs are revolutionizing weight loss globally. This post explores the impact of these medications, their potential benefits beyond weight loss, and how to monitor your health on this journey.
4 min read
Gut-Brain Connection: How Gut Health Impacts Neurodegenerative Disease Risk
New research highlights the critical role of the gut-brain-immune axis in neurodegenerative diseases. Understanding this connection could unlock new approaches for prevention and treatment. Read on for key insights!
4 min read
GLP-1s & Longevity: Exploring the Science Behind Katherine Ryan's Plans
Katherine Ryan's post-pregnancy plans have shone a spotlight on GLP-1 medications. But what's the real science behind them, and how do they fit into the broader picture of metabolic health and longevity? Let's delve into the details.
3 min read
Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read